Adaptimmune
-
Adaptimmune, TCR2 Therapeutics to Combine in Marriage of Cell Therapy Developers
Adaptimmune and TCR2 Therapeutics have complementary technologies and an aligned strategy of developing cell therapies for solid tumors, but this marriage is preceded by divorce. Before consummating the TCR2 deal, Adaptimmune ended an alliance with a larger pharmaceutical company.
-
Adaptimmune’s ASCO data for cell therapy in sarcoma spark optimism about Phase II study potential
One study investigator pointed to the data for ADP-A2M4 as indicating much greater efficacy in the rare cancer than existing therapy options, while another said it demonstrated cell therapies’ potential outside of the blood cancer space.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Market forecasts see easy road ahead for cell therapies in oncology
One report forecasts $25 billion in global sales in six years, but cell therapies to date have been slow to catch on.